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We read, with interest, the comments on our 
News & Views article (Diabetes mellitus: 
Complex interplay between metformin, AKI 
and lactic acidosis. Nat. Rev. Nephrol. 13, 521–
522 (2017))1 by Bell, S. et al. (Clarifying the 
relationship between metformin, acute kidney 
injury and lactic acidosis. Nat. Rev. Nephrol. 
http://dx.doi.org/10.1038/nrneph.2017.172 
(2017))2, and we would like to respond to their 
important points.
First, we concur that metformin should be 
temporarily discontinued in patients with con-
ditions that predispose to acute kidney injury 
(AKI). Although this is not consistently recom-
mended by regulatory bodies and guidelines3,4, 
the studies by Connelly et al. and Bell et al. pro-
vide much-needed evidence for the potential 
toxicity of metformin in this context5,6.
Second, we concur that crude incidence 
rates of lactic acidosis may differ across studies 
that have heterogeneous patient populations. 
However, large observational studies using 
clinical databases may not accurately esti-
mate the real-world incidence of metformin- 
associated lactic acidosis (MALA), particularly 
if ascertained using blood lactate levels ordered 
at the discretion of clinicians (instead of using 
a strict protocol for measurement among all 
study participants) or by diagnostic codes, in 
several ways4,7,8: first, eligibility criteria that 
requires patients to have one lactate measure-
ment for inclusion may miss patients with 
elevated levels of lactate that aren’t measured; 
second, metformin users may undergo more 
frequent lactate measurement than non-users, 
overestimating the risk of MALA; and third, 
the risk of MALA could conversely be under-
estimated owing to confounding by indication, 
as metformin users appeared to be healthier 
than non-users in both the Connelly et al. and 
Bell et al. studies5,6.
Third, regarding the absence of a new-user 
design, we agree that the ability of the study by 
Bell et al. to follow the majority of patients over 
an extended period with prescribing data from 
all pharmacies in the Tayside region is a major 
strength that mitigates potential survivor bias.
Fourth, we concur that the findings of 
‘ever’ versus ‘never’ metformin use and 
risk of AKI may potentially be explained 
by confounding factors (that is, metformin 
as a marker for coexisting comorbidities). 
However, using the summary of table 2  in 
the original study (of patient characteristics 
stratified by time-updated metformin expo-
sure status) as a gauge for the distribution of 
characteristics among metformin ‘ever’ versus 
‘never’ users, there appears to be a tendency 
towards metformin prescription among 
healthier patients.
Finally, we acknowledge that there is wide-
spread debate regarding the use of metformin 
in patients with chronic kidney disease (CKD), 
including the precise threshold at which 
this medication should be restricted4,7–12. 
However, patients with CKD have a greater, 
often unanticipated, susceptibility to AKI and 
a lower underlying reserve of renal function 
when AKI occurs8,13. Furthermore, a large 
proportion of patients with CKD have AKI-
predisposing conditions (for example, infec-
tion and/or sepsis, congestive heart failure 
and myocardial infarction) that further elevate 
their risk of MALA14. It is worth mentioning 
that one study, cited by the investigators in 
their correspondence, showed that there was 
a trend towards higher risk of acidosis and 
serious infection among metformin users 
with an estimated glomerular filtration rate 
(eGFR) <45 ml/min/1.73 m2 (REFS 3,15) and 
that another study16 excluded patients with 
CKD (serum creatinine ≥1.5 mg/dl) or serious 
medical illness. Moreover, the high mortality 
rate from MALA and the multitude of alterna-
tive anti-diabetic pharmacotherapies available 
calls into question whether a small risk of met-
formin justifies its benefit. Although a recent 
rigorous systematic review concluded that lim-
ited evidence suggests that metformin does not 
substantially affect lactate levels when eGFR is 
>30 ml/min/1.73 m2 and that a consistent link 
between metformin and lactic acidosis was 
not observed across available evidence7, fur-
ther studies, including randomized controlled 
trials that test the tolerability and effectiveness 
of metformin in CKD and the precise eGFR 
threshold above which metformin is safe, are 
urgently needed.
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